Kidney ABC

Prior treatment

• Active or planned treatment with a medication that interacts with R3R01
• Immunosuppressive therapy or immunosuppression in the prior 6 months

Other illness

• Polycystic kidney disease, ANCA-associated vasculitis or lupus nephritis
• Any other medical condition(s) that might put the patient at risk or influence study results in the investigators opinion, or that the investigator deems unsuitable for the study including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders sufficient to interfere with the patient’s ability to understand and comply with the protocol instructions or follow-up procedures.
• Ongoing cancer treatment
• Nephrotic syndrome
• Failure to understand patient information or to collaborate with the investigator
• History of hypersensitivity to study drug and/or any of its excipients

Lab values

• Hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption

Other

• Impaired liver function (clinically significant)
• Pregnancy or lactation
• Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study unless they agree to use highly effective contraception

• Male or female adults (above 18 years) with type 2 diabetes (controlled with hemoglobin A1c <10.5%).
• Both female patients, as well as female partners of male patients who are of childbearing potential must be willing to not become pregnant for the complete duration of the study (>180 days) (90 days after the last dose of study medication)
• Males (including sterilized subjects) whose female partners have child-bearing potential, must agree to use male contraception (condoms) during the period from the time of signing the informed consent form (ICF) through 90 days after the last dose of study drug. They must agree to immediately inform the investigator if their partner becomes pregnant during the study
• Stable antihypertensive treatment 4 weeks before start of study drug and throughout study duration.
• Titrated to the maximal dose or maximal tolerated dose of renin-angiotensin blocking treatment.
• Stable treatment with lipid lowering agents for at least 4 weeks.
• People on SGLT2-Inhibitors should be on stable dose of the drug for at least 3 months
• UACR >30 mg/g and < 5000 mg/g on two consecutive measurements
• eGFR >30 ml/min/1.73 m2 (CKD-EPI formula)
• Abdominal obesity (Waist circumference) Women: > 80 cm, Men: > 95 cm or fasting triglyceride >2.0 mmol/l based on historic laboratory values within 2 years before screening.
• Systolic blood pressure ≥110 mmHg and ≤160 mmHg.